Vor Biopharma (NASDAQ:VOR) Director Sells $13,041.00 in Stock

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 828 shares of the stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $15.75, for a total transaction of $13,041.00. Following the sale, the director directly owned 3,935,608 shares of the company’s stock, valued at $61,985,826. This represents a 0.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, April 9th, Ra Capital Management, L.P. sold 135,201 shares of Vor Biopharma stock. The stock was sold at an average price of $16.59, for a total value of $2,242,984.59.
• On Wednesday, April 8th, Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma stock. The stock was sold at an average price of $16.48, for a total value of $7,978,033.92.
• On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The stock was sold at an average price of $16.59, for a total value of $9,775,773.63.
• On Thursday, April 2nd, Ra Capital Management, L.P. sold 260,000 shares of Vor Biopharma stock. The stock was sold at an average price of $18.23, for a total value of $4,739,800.00.

Vor Biopharma Stock Performance

NASDAQ VOR opened at $15.47 on Monday. The firm has a market capitalization of $755.71 million, a P/E ratio of -0.04 and a beta of 1.92. The business has a fifty day simple moving average of $14.41 and a 200 day simple moving average of $16.94. Vor Biopharma Inc. has a 12 month low of $2.62 and a 12 month high of $65.80.

Institutional Investors Weigh In On Vor Biopharma

Several large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Vor Biopharma during the 4th quarter valued at $36,000. Bank of America Corp DE increased its position in shares of Vor Biopharma by 679.3% during the 3rd quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock valued at $232,000 after purchasing an additional 4,144 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Vor Biopharma during the 3rd quarter valued at $230,000. BNP Paribas Financial Markets increased its position in shares of Vor Biopharma by 497.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after purchasing an additional 5,058 shares during the last quarter. Finally, Bridgeway Capital Management LLC purchased a new stake in shares of Vor Biopharma during the 3rd quarter valued at $304,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on VOR. Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Wells Fargo & Company began coverage on Vor Biopharma in a research report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price target for the company. TD Cowen began coverage on Vor Biopharma in a research report on Wednesday, December 17th. They issued a “buy” rating for the company. Citigroup began coverage on Vor Biopharma in a research report on Friday, January 9th. They issued a “buy” rating and a $50.00 price target for the company. Finally, Jefferies Financial Group began coverage on Vor Biopharma in a research report on Monday, March 30th. They issued a “buy” rating and a $50.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.67.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).